Synopsis Ovarian cancer accounts for about 3.6% of cancers in women worldwide. It ranks eighth as the cause of death in women with cancer and has the highest rate of mortality among all the gynecologic cancers in the western world. Despite treatments like cytoreductive surgery (CRS) and intravenous platinum-based chemotherapy, almost 80% of patients with advanced-stage disease experience a recurrence within two years. This ‘MEDFACT’ presents a summary of 'A randomized, open-labeled, phase 3 trial of adding HIPEC in patients who are treated with secondary debulking surgery in Stage III epithelial ovarian cancer’ from “The New England Journal Of Medicine’’ Authors: W.J. van Driel, S.N. Koole, K.
Sikorska, J.H. Schagen van Leeuwen et. al. What was the need for this study? Previous trials have demonstrated a recurrence-free and overall survival from adjuvant intraperitoneal chemotherapy…
